SOLV Stock Analysis — Solventum
Sector: Healthcare
AI Verdict
SOLV is cheap for the sector at 12.9x forward earnings, but the negative growth outlook means you’re betting the supply chain moat can offset shrinking profits.
Competitive Moat
Solventum manufactures medical and surgical products, with a defensible position in hospital supply chains due to long-term contracts and high switching costs for critical consumables. Its entrenched relationships with healthcare providers make it difficult for new entrants to displace its products quickly.
Summary
Solventum's stock is running hot after a 27.71% gain in the past year, but earnings are expected to shrink next year.
Where It Stands
SOLV trades at 12.9x next year's earnings, well below the healthcare sector median of 22x, even as its RSI of 71.2 signals overbought conditions after a 27.71% 1-year return.
Key Metrics
- RSI: 71.2 — Overbought
- Trailing P/E: 11.3x
- Forward P/E: 12.9x
- Earnings Growth: -0.1%
- Revenue Growth: -0.0%
- Market Cap: $15.7B
- 1-Year Return: 27.71%
- 52-Week High: $94.16
- 52-Week Low: $62.38
Analyst Consensus
13 Buy · 8 Hold · 1 Sell (22 analysts)
Bull Case
At 12.9x forward earnings, you’re paying much less than the sector median for a business with sticky hospital contracts.
Bear Case
With forward EPS expected to drop -12.5% and an RSI of 71.2, a pullback could easily erase a chunk of the recent 27.71% gain if sentiment cools.
Catalyst to Watch
Watch for quarterly earnings updates — if EPS declines less than the -12.5% expected, the valuation discount could narrow.